Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience? $28.90 in Sight? 📈
At $24.04 (+0.04%), PFE offers a compelling entry with its low P/E of 12.72 and robust 7.15% dividend yield, trading well below analyst targets of $28.90 (20% upside potential)—could resilient economic forecasts boost healthcare demand and spark a rally? 🚀
**Fundamental Analysis**
Pfizer boasts EPS (TTM) of $1.89 and revenue (TTM) of $63.83B, with a PEG ratio of 0.96 signaling undervaluation relative to growth prospects; DCF models suggest intrinsic value above current levels given strong cash flows of $16.02B, though patent expirations weigh on margins.
- **Positive:** High dividend yield supports income-focused portfolios; diversified pipeline in oncology and vaccines drives long-term revenue stability.
- **Negative:** Elevated enterprise value/EBITDA at 9.15 reflects debt from acquisitions; regulatory hurdles could delay new approvals.
**SWOT Analysis**
**Strengths:** Broad product portfolio and global reach; strong R&D investment.
**Weaknesses:** High debt levels post-acquisitions; dependency on blockbuster drugs.
**Opportunities:** Expanding into emerging markets amid economic growth; AI-driven drug discovery partnerships.
**Threats:** Generic competition; geopolitical tensions impacting supply chains.
**Technical Analysis**
Chart shows consolidation in a tight range with emerging bullish momentum. Price: $24.04, VWAP $24.10.
Key indicators:
- RSI: 45 (neutral, room for upside without overbought risk).
- MACD: Positive crossover signaling building momentum.
- Moving Averages: 50-day at $25 (potential breakout level), 200-day at $26 (long-term trendline).
Support/Resistance: Support at $23, resistance at $25. Patterns/Momentum: Ascending triangle forming, favoring bulls on volume increase. 📈 Bullish | ⚠️ Bearish.
**Scenarios and Risk Management**
- **Bullish:** Entry above $25 on volume, DCA in dips to average down for 20% upside to targets.
- **Bearish:** Drop below $23 on weak earnings, exit positions.
- **Neutral:** Sideways trade between support/resistance amid macro waits.
Risk Tips: Set stops at 5% below entry, limit position to 2-3% of portfolio, diversify across sectors, and apply DCA to mitigate volatility. ⚠️
**Conclusion/Outlook**
Bullish bias if economic resilience sustains healthcare spend. Watch Fed remarks. Fits value theme with #Economy upside. Take? Comment!
At $24.04 (+0.04%), PFE offers a compelling entry with its low P/E of 12.72 and robust 7.15% dividend yield, trading well below analyst targets of $28.90 (20% upside potential)—could resilient economic forecasts boost healthcare demand and spark a rally? 🚀
**Fundamental Analysis**
Pfizer boasts EPS (TTM) of $1.89 and revenue (TTM) of $63.83B, with a PEG ratio of 0.96 signaling undervaluation relative to growth prospects; DCF models suggest intrinsic value above current levels given strong cash flows of $16.02B, though patent expirations weigh on margins.
- **Positive:** High dividend yield supports income-focused portfolios; diversified pipeline in oncology and vaccines drives long-term revenue stability.
- **Negative:** Elevated enterprise value/EBITDA at 9.15 reflects debt from acquisitions; regulatory hurdles could delay new approvals.
**SWOT Analysis**
**Strengths:** Broad product portfolio and global reach; strong R&D investment.
**Weaknesses:** High debt levels post-acquisitions; dependency on blockbuster drugs.
**Opportunities:** Expanding into emerging markets amid economic growth; AI-driven drug discovery partnerships.
**Threats:** Generic competition; geopolitical tensions impacting supply chains.
**Technical Analysis**
Chart shows consolidation in a tight range with emerging bullish momentum. Price: $24.04, VWAP $24.10.
Key indicators:
- RSI: 45 (neutral, room for upside without overbought risk).
- MACD: Positive crossover signaling building momentum.
- Moving Averages: 50-day at $25 (potential breakout level), 200-day at $26 (long-term trendline).
Support/Resistance: Support at $23, resistance at $25. Patterns/Momentum: Ascending triangle forming, favoring bulls on volume increase. 📈 Bullish | ⚠️ Bearish.
**Scenarios and Risk Management**
- **Bullish:** Entry above $25 on volume, DCA in dips to average down for 20% upside to targets.
- **Bearish:** Drop below $23 on weak earnings, exit positions.
- **Neutral:** Sideways trade between support/resistance amid macro waits.
Risk Tips: Set stops at 5% below entry, limit position to 2-3% of portfolio, diversify across sectors, and apply DCA to mitigate volatility. ⚠️
**Conclusion/Outlook**
Bullish bias if economic resilience sustains healthcare spend. Watch Fed remarks. Fits value theme with #Economy upside. Take? Comment!
Trade active
⚡️ Request a trial or subscribe to our premium🛠️tools at ➡️DCAlpha.net
All scripts & content provided by DCAChampion are for informational & educational purposes only.
All scripts & content provided by DCAChampion are for informational & educational purposes only.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
⚡️ Request a trial or subscribe to our premium🛠️tools at ➡️DCAlpha.net
All scripts & content provided by DCAChampion are for informational & educational purposes only.
All scripts & content provided by DCAChampion are for informational & educational purposes only.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.